IDEAYA Achieves First Milestone In GSK Pact For Pol Theta Helicase Inhibitor Candidate

IDEAYA Biosciences Inc IDYA has achieved a preclinical development milestone in connection with ongoing IND-enabling studies for its Pol Theta Helicase Development Candidate.
IDEAYA is collaborating with GSK plc GSK on IND-enabling studies to support the evaluation of the Pol Theta Helicase DC in combination with niraparib for BRCA harboring tumors or other homologous recombination mutations or homologous recombination deficiency.
IDEAYA and GSK are targeting an IND submission for the Pol Theta Helicase candidate to enable first-in-human studies in the first half of 2023.
Earlier this month, the company retained worldwide rights to IDE397 following GSK's waiver of its option to an exclusive license to further develop and commercialize IDE397.
GSK will lead clinical development for the Pol Theta program under its global license to develop and commercialize the Pol Theta Helicase Inhibitor.
GSK is responsible for all research and development costs for the program. IDEAYA is eligible to receive total development and regulatory milestones of up to $485 million.
Upon potential commercialization, IDEAYA will be eligible to receive up to $475 million of commercial milestones and tiered royalties on global net sales by GSK.
Price Action: IDYA shares are up 3.33% at $9.93 on the last check Monday.